T1	Participants 374 421	A teaching hospital and tertiary medical center
T2	Participants 434 526	Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups
T3	Participants 528 646	These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix
T4	Participants 1088 1120	Patients with premature LH surge
T5	Participants 50 85	premature luteinizing hormone surge
